ROCKVILLE, Md.--(BUSINESS WIRE)--
BIOQUAL ((OTC Pink: BIOQ) ():
|
2020 |
|
2019 |
|
||
Revenue |
$ |
46,360,201 |
$ |
39,478,079 |
|
|
Income Before Income Tax |
$ |
5,488,938 |
$ |
3,709,246 |
|
|
Net Income |
$ |
4,230,938 |
$ |
2,830,875 |
|
|
Basic Earnings per Share |
|
|
|
|||
of Common Stock |
$ |
4.74 |
$ |
3.17 |
||
Diluted Earnings per Share |
|
|
|
|||
of Common Stock |
$ |
4.73 |
$ |
3.17 |
||
Weighted Average |
|
|
|
|||
Number of Shares Outstanding |
|
|
||||
For Basic Per Share |
|
893,416 |
|
893,416 |
||
Weighted Average |
|
|
|
|||
Number of Shares Outstanding |
|
|
||||
For Diluted Earnings Per Share |
|
893,971 |
|
893,655 |
||
BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020. This is the nineteenth dividend declared by BIOQUAL.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com:
